Preclinical studies have shown that inhibiting autophagy via siRNA against beclin 1 and ATG5, or pharmacological inhibitors such as 3-MA, increase the efficacy of radiotherapy in breast cancer, glioma, colorectal, and oesophageal cancer cells25–27. Here, ATG5 is linked to breast carcinoma.